SCHEMBL3763667

SCHEMBL3763667

C1=CC2CNCCN2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7159626 0.77
SCHEMBL21590897 0.72
SCHEMBL20456725 0.71 HTR6 (0.34)
SCHEMBL1190286 0.71 HTR6 (0.34)
SCHEMBL22524926 0.69
SCHEMBL3810430 0.68 HTR6 (0.44)
SCHEMBL4977845 0.67 HTR6 (0.38)
SCHEMBL17748322 0.65
SCHEMBL18692324 0.65
SCHEMBL9687115 0.65 HPGD (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0520320-B1 Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO (JP) 1997-09-10 EP claimed
EP-0520320-A2 Tetrahydropyrrolo 1,2-a pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1992-12-30 EP claimed
US-12600728-B2 Interleukin-17 inhibitors NOVARTIS AG (CH) 2026-04-14 US disclosed
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250270172-A1 Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2025-08-28 US disclosed
US-20250122225-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-17 US disclosed
US-20230391782-A1 INTERLEUKIN-17 INHIBITORS NOVARTIS AG (CH) 2023-12-07 US disclosed
US-8435978-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2013-05-07 US disclosed
US-20100324009-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-23 US disclosed
US-20100317644-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-16 US disclosed
EP-2148673-A1 CINNAMIDE COMPOUNDS FOR DEMENTIA Eisai R&D Management Co., Ltd. (JP) 2010-02-03 EP disclosed
WO-2008139984-A1 CINNAMIDE COMPOUNDS FOR DEMENTIA EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-11-20 WO disclosed
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2008-06-26 US disclosed
EP-0520320-B1 Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO (JP) 1997-09-10 EP disclosed
US-5378846-A Anxiolytic agents RUSSIAN-AMERICAN INSTITUTE FOR NEW DRUG DEVELOPMENT (US) 1995-01-03 US disclosed
WO-1994029315-A1 1,2,3,4-TETRAHYDROPYRROLO[1,2-a]PYRAZINES THE RUSSIAN-AMERICAN INSTITUTE FOR NEW DRUG DEVELOPMENT (US) 1994-12-22 WO disclosed
US-5258382-A Antidiabetic agents or reductase inhibitors DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1993-11-02 US disclosed
EP-0520320-A2 Tetrahydropyrrolo 1,2-a pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1992-12-30 EP disclosed